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Abstract
 
T cells secreting interleukin (IL)-4 and IL-5 (T helper cell type 2 [Th2] cells) play a detri-
mental role in a variety of diseases, but specific methods of regulating their activity remain
elusive. T1/ST2 is a surface ligand of the IL-1 receptor family, expressed on Th2- but not on
 
interferon (IFN)-
 
g
 
–producing Th1 cells. Prior exposure of BALB/c mice to the attachment
(G) or fusion (F) protein of respiratory syncytial virus (RSV) increases illness severity during
intranasal RSV challenge, due to Th2-driven lung eosinophilia and exuberant Th1-driven
pulmonary infiltration, respectively. We used these polar models of viral illness to study the
recruitment of T1/ST2 cells to the lung and to test the effects of anti-T1/ST2 treatment in
 
vivo. T1/ST2 was present on a subset of CD4
 
1
 
 cells from mice with eosinophilic lung dis-
ease. Monoclonal anti-T1/ST2 treatment reduced lung inflammation and the severity of ill-
ness in mice with Th2 (but not Th1) immunopathology. These results show that inhibition
of T1/ST2 has a specific effect on virally induced Th2 responses and suggests that therapy
targeted at this receptor might be of value in treating Th2-driven illness.
 
Key words: bronchiolitis, viral • immunity, mucosal • immunity, cellular • pulmonary infection • 
eosinophil
 
Introduction
 
In several common diseases, some CD4
 
1
 
 T cells cause en-
hanced pathology, while others are protective. Th1 cells
 
produce IFN-
 
g
 
, activate macrophages, and are associated
with inflammatory disorders, whereas Th2 cells secrete pre-
dominantly IL-4 and IL-5 and are pivotal in asthma and
atopy (1–3). Selective depletion of Th1 or Th2 cells would
provide a novel therapeutic strategy but requires the identi-
fication of reliable markers and targets against which ther-
apy could be directed.
 
To date, the Th1 phenotype is associated with chemokine
receptor 1, 3, and 5 (references 4 and 5) and IL-18 receptor
expression (6). The Th2 phenotype, on the other hand,
preferentially upregulates the transcription factors c-maf (7)
and GATA-3 (8), chemokine receptors 3 and 4 (references
4, 9, and 10), and the orphan receptor T1/ST2 (references
11–15). Resting murine Th2 cells constitutively express the
multidrug resistance protein transmembrane pump, whereas
expression on Th1 and Th2 cells is equal after antigenic
stimulation (16–17). Recently, a novel leukocyte chemoat-
tractant receptor expressed on activated human Th2 but not
Th1 cells has been reported (designated CRTH2, chemoat-
tractant receptor-homologous molecule expressed on Th2
cells). Allergen-induced proliferation of peripheral blood
mononuclear cells is significantly reduced by antibody-medi-
 
ated depletion of CRTH2
 
1
 
 cells (18).
T1/ST2 is an IL-1 receptor family member originally
identified in murine fibroblasts (19–20). Alternate 3
 
9
 
 pro-
cessing generates a long and short mRNA. The short
mRNA encodes a secreted glycoprotein that is constitu-
tively expressed in embryonic tissues and mammary tumors
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and is inducible in fibroblasts. The long mRNA encodes a
membrane-spanning protein expressed only in the lung and
hematopoietic tissue (21–23). Studies of T1/ST2 knockout
mice provide conflicting evidence regarding its functional
significance (24–26). Anti-T1/ST2 treatment of immuno-
competent mice partially inhibits Th2 differentiation and
allergic airway inflammation (13), but the effects of anti-
T1/ST2 treatment have not been evaluated in virus-
infected animals.
Respiratory syncytial virus (RSV)
 
1
 
 is a common cold vi-
rus that causes bronchiolitis in infants, killing up to one
million children per year worldwide (27). Children hospi-
talized with bronchiolitis often suffer recurrent wheezing in
later childhood and are frequently diagnosed as asthmatic
(28). There is strong evidence that viral bronchiolitis is a T
cell–mediated immunopathological condition (29, 30). In
the BALB/c mouse, primary intranasal infection with RSV
causes mild self-limiting illness characterized by transient T
cell infiltration. However, prior sensitization to the attach-
ment protein (G; expressed by recombinant vaccinia virus)
results in extensive lung eosinophilia and enhanced weight
loss after RSV challenge. CD4
 
1
 
 T cells secreting IL-4 and
IL-5 are necessary and sufficient for this response (31). This
phenomenon is reminiscent of human vaccine trials using
formalin-inactivated RSV that caused disease enhancement
and peripheral and lung eosinophilia and lead to some
deaths in RSV-infected vaccinees (29). After sensitization
with the fusion (F) protein, an exuberant T cell infiltrate
causes enhanced weight loss, but eosinophil recruitment is
not seen (32). A major advantage of the BALB/c model is
that immune responses can be manipulated in parallel
groups of mice undergoing Th1- or Th2-mediated pathol-
ogy to the same pathogen.
We now report that CD4
 
1
 
 T cells expressing T1/ST2
occur exclusively during the Th2-driven eosinophilic RSV
disease and are reduced in number by treatment with IL-12
(which antagonizes the development of eosinophilia). Fur-
thermore, treatment of mice with anti-T1/ST2 antibody
decreases inflammatory cell recruitment and weight loss
only in mice with eosinophilic immunopathology. These
results indicate that T1/ST2
 
1
 
 cells are specifically associ-
ated with RSV-induced eosinophilia in this model and that
blockade of this cell surface receptor may be of therapeutic
use in Th2-driven illnesses.
 
Materials and Methods
 
Generation of mAb 3E10.
 
The generation and characteriza-
tion of rat anti-T1/ST2 mAb (clone 3E10) is described elsewhere
(15). In brief, a DNA sequence containing the extracellular do-
main of T1/ST2 was amplified by PCR and cloned into a vector
containing the CD5 signal sequence and the human IgG1 con-
stant region. COS cells were transiently transfected by using the
LipofectAMINE™ (GIBCO BRL) protocol and cultured in Ul-
tra Low IgG Fetal Bovine Serum™ (GIBCO BRL) for 1 wk.
 
Recombinant protein was purified from culture supernatants us-
ing a protein A column. Lou/M rats were immunized with 0.5
mg of purified recombinant T1/ST2 subcutaneously, followed by
intraperitoneal boosting twice at 2-wk intervals. Sera were ana-
lyzed for reactivity to the fusion protein by ELISA 10 d after the
final boost. Animals with serum antibody to T1/ST2 were
boosted again 4 wk later and killed after a further 3 d. Spleno-
cytes were fused with SP/2 myeloma cells, and resulting clones
were screened for selective binding to murine Th2 clones. The
hybridoma 3E10 produced a blocking rat IgG1 anti-T1/ST2
mAb. Serum from unimmunized Lou/M rats was used as nega-
tive control.
 
Mice and Virus Stocks.
 
8–10-wk-old female BALB/c mice
were purchased from Harlan Olac Ltd. and kept in pathogen-free
conditions. RSV and recombinant vaccinia virus expressing the
attachment protein (Gvac) or the fusion protein (Fvac) of RSV or
control 
 
b
 
-galactosidase (
 
b
 
 gal-vac) were grown in HEp-2 cells
and assayed for infectivity as previously described (33). All stocks
were mycoplasma free as assessed by DNA hybridization (Gen-
Probe Inc.).
 
Mouse Infection and Treatment.
 
Anesthetized mice were scari-
fied on the rump on day 0 with 3 
 
3
 
 10
 
6
 
 pfu Gvac, Fvac, or 
 
b
 
gal-vac in a final volume of 10 
 
m
 
l (four or five mice per group).
On day 14, mice were challenged intranasally with 3 
 
3
 
 10
 
6
 
 pfu
of human RSV (A2 strain). Some mice were injected intrave-
nously with 100 
 
m
 
g of anti-T1/ST2 (rat IgG) or isotype-matched
control antibody each day, starting 1 d before RSV challenge. In
addition, some mice were treated with recombinant IL-12 (300
ng in PBS) daily from day 
 
2
 
2 to day 
 
1
 
2 relative to scarification
as described previously (34). The appearance of illness was scored
by a blinded observer, and the weights of mice were monitored
daily after RSV challenge. Illness was scored using the following
scale: 0 
 
5
 
 healthy; 1 
 
5 
 
barely ruffled fur; 2 
 
5
 
 ruffled fur but ac-
tive; 3 
 
5 
 
ruffled fur and inactive; 4 
 
5 
 
ruffled fur, inactive, and
hunched; and 5 
 
5
 
 dead. Mice were killed on day 21 (7 d after in-
tranasal RSV challenge) by injection of 3 mg of pentobarbitone
and exanguinated via the femoral vessels.
 
Lung Virus Titer.
 
Clearance of RSV was assessed in lung ho-
mogenates on days 2 and 4 after virus challenge. Lungs were re-
moved from four mice per group and homogenized. After centrif-
ugation at 4,000 rpm for 4 min, the supernatant was titrated in
doubling dilutions on HEp-2 cell monolayers in 96-well flat-bot-
tomed plates. 24 h later, monolayers were washed and incubated
with peroxidase-conjugated goat anti-RSV antibody (Biogenesis).
Infected cells were detected using 3-amino-9-ethylcarbazole
(AEC), and infectious units were enumerated by light microscopy.
 
Cell Recovery.
 
After sacrifice, bronchoalveolar lavage (BAL)
fluid, lung tissue, and serum were harvested as previously de-
scribed (35). In brief, the lungs of each mouse were inflated six
times with 1 ml of 12 mM lidocaine in Eagle’s MEM and placed
undiluted on ice in sterile tubes. 100 
 
m
 
l of BAL fluid from each
mouse was cytocentrifuged onto glass slides, and eosinophils were
enumerated using hematoxylin and eosin staining based on cell
morphology and presence of red granules. The remainder of the
BAL fluid was centrifuged, and the supernatant was removed and
stored at 
 
2
 
70
 
8
 
C in 200-
 
m
 
l aliquots for analysis of cytokines by
ELISA. The pelleted cells were resuspended in RPMI containing
10% FCS, 2 mM/ml 
 
l
 
-glutamine, 50 U/ml penicillin, and 50
mg/ml streptomycin (R10F). Viable cells were counted by try-
pan blue exclusion
 
Flow Cytometric Analysis.
 
T1/ST2 antibody (2
 
 m
 
g) or control
antibody was added to 10
 
6
 
 pelleted cells on ice for 30 min; cells
were then washed and treated with goat anti–rat FITC (Sigma-
 
1
 
Abbreviations used in this paper: 
 
BAL, bronchoalveolar lavage; RSV, respi-
ratory syncytial virus.
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Aldrich). After blocking with rat serum, Quantum Red™–con-
jugated CD8 or B220 and PE-conjugated CD4 or DX5 (anti-
NK cell antibody) (Sigma-Aldrich) were added for 30 min. After
washing again, cells were fixed for 20 min at room temperature
with 2% formaldehyde. Samples were analyzed on a Beckman
Coulter EPICS Elite™ flow cytometer collecting data on at least
40,000 lymphocytes. Eosinophils were enumerated as granulo-
cytes by flow cytometry using their distinctive forward and side
scatter properties.
 
Cytokine ELISAs.
 
IL-4, IL-5, IFN-
 
g
 
, and TNF-
 
a
 
 in BAL
fluid were quantified using OptEIA™ kits from PharMingen. In
brief, microtiter plates were coated with 100 
 
m
 
l of capture anti-
body diluted in the recommended buffer overnight at 4
 
8
 
C. After
five washes with PBS containing 0.5% Tween-20, plates were
blocked with 200 
 
m
 
l of PBS containing 10% FCS and left for 1 h
at room temperature. Samples and standards (diluted in PBS plus
10% FCS) were then incubated for a further 2 h at room temper-
ature. After five washes, bound cytokine was detected using bi-
otinylated antibodies premixed with avidin–horseradish peroxi-
dase followed by tetramethylbenzidine and hydrogen peroxidase.
Optical densities were read at 450 nm. The mean optical density
of wells containing no cytokine was subtracted from the results
obtained for samples and standards. The concentration of cyto-
kine in each sample was calculated from a standard curve using
linear regression analysis. The standard curve range for IL-4 lies
between 7.8 and 500 pg/ml, for IL-5 between 15.6 and 1,000
pg/ml, for TNF between 15.6 and 1,000 pg/ml, and for IFN-
 
g
 
between 31.3 and 2,000 pg/ml.
 
RSV-specific Antibody ELISA.
 
Serum antibody was assessed
by ELISA as described previously (36). ELISA antigen was pre-
pared by infecting HEp-2 cells with RSV strain A2 at 1 pfu/cell.
When significant cytopathic effect was observed the infected cells
were harvested, centrifuged at 400 
 
g
 
, resuspended in 3 ml of dis-
tilled water, and then subjected to 2 min of sonication (Ultra-
wave Ltd.). Uninfected HEp-2 cells were similarly treated and
used as control antigen. 50-
 
m
 
l aliquots were stored at 
 
2
 
20
 
8
 
C un-
til required. Microtiter plates were coated overnight with 100 
 
m
 
l
of a 1:200 dilution of either sonicated RSV or HEp-2 control an-
tigen. After blocking with 2% normal rabbit serum for 2 h, dilu-
tions of test samples (diluted in PBS containing 1% HEp-2 lysate)
were added for a further hour at room temperature. Bound anti-
body was detected using peroxidase-conjugated rabbit anti–
mouse Ig and
 
 O
 
-phenylene-diamine as a substrate. The reaction
was stopped with 50 
 
m
 
l of 2.5 M sulfuric acid. Optical densities
were read at 490 nm. The amount of RSV-specific antibody was
determined by subtracting the optical density obtained by incu-
bating serum on HEp-2–coated plates from the same sample in-
cubated on RSV-coated plates.
 
Statistical Analysis.
 
One-way ANOVA (analysis of variance)
assuming unequal variance was used and significance assumed at
 
P 
 
,
 
 0.05.
 
Results
 
To simplify the description in Results and Discussion,
we will refer to Gvac-primed, RSV-challenged mice as
G/RSV, Fvac-primed, RSV-challenged mice as F/RSV,
and control 
 
b
 
 gal-vac–primed, RSV-challenged mice as 
 
b
 
gal/RSV.
 
T1/ST2
 
1
 
 Cells Are Present in the BAL during Eosinophilic
Illness.
 
No T1/ST2
 
1
 
 cells were observed in the lungs of
uninfected mice (data not shown). T1/ST2
 
1
 
 cells were ap-
 
parent 3 d after RSV challenge in G/RSV (which showed
lung eosinophilia) but not F/RSV mice (which did not have
lung eosinophilia). T1/ST2
 
1
 
 cells were CD4
 
1
 
 (4.4% of
CD4
 
1
 
 T cells at day 3; Fig. 1 A) and did not express CD8,
B220 (CD45R), or DX5 (data not shown). The number of
T1/ST2
 
1
 
 cells in the lungs peaked at day 5 after RSV chal-
lenge in G/RSV mice (13.3% of CD4
 
1
 
 T cells; Fig. 1 B)
and were mostly CD45RB low (
 
.
 
90%), indicating recent
activation. A small population of T1/ST2
 
1
 
 cells were CD4
 
2
 
but did not express any of the other lymphoid markers de-
scribed above. It is possible that these cells have downregu-
lated CD4 expression after antigen activation. These data
show that T1/ST2
 
1
 
 cells are present only in the lungs of
mice undergoing eosinophilic inflammatory responses.
 
Anti-T1/ST2 Treatment Prevents Enhanced Illness in G/RSV
but Not in F/RSV Mice.
 
During a primary RSV infection,
BALB/c mice experience mild weight loss after 5–6 d, co-
inciding with the peak of the inflammatory infiltrate. In
G/RSV or F/RSV mice, the inflammatory infiltrate is
greater and weight loss is enhanced and accelerated. How-
ever, anti-T1/ST2 treatment only prevented weight loss in
G/RSV (eosinophilic) animals and had no effect on F/RSV
(noneosinophilic) mice (Fig. 2). Similarly, there was no ef-
fect of anti-T1/ST2 treatment in 
 
b
 
 gal/RSV mice under-
going a primary RSV infection (data not shown).
Figure 1. T1/ST21 cells are present in the lung during viral induced
eosinophilia. Mice were scarified with Gvac and challenged intranasally
with RSV 14 d later. T1/ST21 cells were identified in BAL samples by
indirect immunofluorescence. Cells were then blocked with rat Ig and
stained with quantum red conjugated antibodies to CD4. Samples were
analyzed on a Beckman Coulter EPICS Elite™ flow cytometer collecting
data on at least 40,000 cells. A and B show T1/ST21 cells in G/RSV mice
at days 3 and 5 after intranasal RSV challenge. C and D show G/RSV
mice treated with PBS (C) or IL-12 (D) at 4 d after intranasal RSV chal-
lenge. Representative plots for five mice per group are shown.
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Anti-T1/ST2 Treatment Reduces Inflammatory Cell Influx
and BAL Cytokine Levels in G/RSV but Not in F/RSV
Mice.
 
Anti-T1/ST2
 
1
 
 treatment significantly reduced total
BAL cell recovery from G/RSV mice, affecting eosino-
phils, lymphocytes, CD4
 
1
 
 T cells, and CD8
 
1
 
 T cells (Fig.
3). The reduction of eosinophils was particularly promi-
nent, as both the proportion and total number present in
the sample were reduced by anti-T1/ST2 treatment. A
corresponding reduction in BAL fluid TNF, IL-5, and
IFN-
 
g
 
 (but not IL-4) was also observed (Fig. 4). Anti-T1/
ST2 treatment had no significant effect on cell recruitment
or phenotype in F/RSV mice (
 
P
 
 
 
.
 
 0.05 for all compari-
sons; Fig. 5). Furthermore, no T1/ST2-expressing cells
were found in the BAL of anti-T1S/T2–treated mice (data
not shown).
 
Anti-T1/ST2 Treatment Reduces RSV-specific Antibody and
Viral Clearance in G/RSV but Not F/RSV Mice.
 
Prior
scarification with Gvac or Fvac induces enhanced virus-
specific antibody production after RSV challenge com-
pared with mice infected with RSV alone. Anti-T1/ST2
treatment reduced this boost in antibody levels in G/RSV
but not F/RSV mice (Table I). The reduction in inflam-
matory infiltrate and antibody titer was reflected by the de-
layed clearance of RSV from the lung in anti-T1/ST2–
treated animals. On day 2 after RSV challenge, there was
no difference in the titer of RSV recovered from the lungs
of treated and untreated mice. However, G/RSV-infected
mice treated with anti-T1/ST2 had reduced viral clearance
at day 4 compared with untreated mice (
 
P
 
 
 
.
 
 0.01), but
treatment did not affect RSV clearance in F/RSV animals
(
 
P
 
 
 
.
 
 0.05) (Fig. 6). No virus was recovered from any
group at day 7 or 10 after RSV infection.
 
G/RSV Mice Treated with Recombinant IL-12 Have Re-
duced Numbers of T1/ST2
 
1
 
 Cells.
 
We have previously
shown that IL-12 treatment reduces pulmonary eosino-
philia but also enhances the weight loss and illness in ani-
mals infected with G/RSV (34). We therefore tested the
effect of IL-12 on the recruitment of T1/ST2
 
1
 
 cells to the
lung. Mice were scarified with Gvac on day 0 and treated
intraperitoneally with IL-12 or PBS daily from day 
 
2
 
2 to
day 
 
1
 
2. In this experiment, 10.5% of CD4
 
1 BAL T cells
expressed T1/ST2 on day 4 of RSV infection (Fig. 1 C);
Figure 2. Anti-T1/ST2 treat-
ment prevents RSV-induced
weight loss during immune re-
sponses dominated by Th2-
driven eosinophilia. Mice were
primed with Gvac, Fvac, or b
gal-vac and challenged with RSV
intranasally 14 d later. Half of
each group was given anti-T1/
ST2 antibody daily from the day
before intranasal RSV challenge
(open symbols), whereas the
other half was given isotype-
matched irrelevant antibody
(closed symbols). The percent
weight loss or gain on subsequent
days was calculated from the
original weight of each individual
mouse. The mean and standard
deviation of five individual mice
are shown (A). The data for b
gal/RSV mice treated with anti-
T1/ST2 is not shown for clarity,
but weight loss was not signifi-
cantly different from control
treated b gal/RSV mice. In B, a
separate experiment with just
G/RSV-infected mice is shown.
Each line represents an individual
mouse treated with anti-T1/ST2
(dotted line) or irrelevant iso-
type-matched control (solid line).
Figure 3. Anti-T1/ST2 treat-
ment reduces inflammation in the
lung. G/RSV-infected mice were
treated with rat Ig (closed symbols)
or anti-T1/ST2 (open symbols), and
cells from the airways were re-
moved by BAL. Total viable cells
were determined by trypan blue ex-
clusion. Total lymphocytes were
calculated by multiplying this num-
ber by the percent lymphocytes
identified in forward and side scatter
plots by flow cytometry (the posi-
tion of lymphocytes being deter-
mined by expression of T and B cell
markers). In the BAL, both total cell
numbers (P 5 0.02) and lympho-
cyte numbers (P 5 0.03) were de-
creased in the anti-T1/ST2–treated
group. (A). The percent of BAL
eosinophils (B) was determined by
differential counting in hematoxylin
and eosin–stained cytocentrifuge
preparations (identified by nuclear
morphology and presence of eosin-
ophilic granules). The data repre-
sents this percentage multiplied by
the total viable cell count and is
lower in the anti-T1/ST2 treated
group (P 5 0.005). The number of
CD41 and CD81 T cells (C) is cal-
culated by multiplying the percent
of each subset (by flow cytometry)
by the number of lymphocytes
present. Both CD41 (P 5 0.02) and CD81 T cells (P 5 0.03) are fewer
in anti-T1/ST2–treated mice. Each point represents an individual mouse
from one of two independent experiments.
Figure 4. Anti-T1/ST2 treatment
reduces cytokine production in the
lung. G/RSV-infected mice were
treated with rat Ig control (solid bars)
or anti-T1/ST2 (open bars). Lung la-
vage was performed 7 d after RSV
challenge, and the cytokines in the
BAL supernatant were assayed by
ELISA. The results represent the
mean and standard deviation of four
mice per group and are representative
of two independent experiments.
Anti-T1/ST2 treatment decreases
TNF (P 5 0.04), IFN-g (P 5 0.029),
and IL-5 (P 5 0.04), but not IL-4.
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IL-12 treatment reduced this figure to ,1% (Fig. 1 D).
Similar to previous reports (34), IL-12 treatment enhanced
cellular recruitment to the lung in the G/RSV group,
which was not significantly affected by anti-T1/ST2 treat-
ment (Fig. 7 A). IL-12 treatment caused a reduction in pul-
monary eosinophilia (P 5 0.005), which was unaffected by
the additional depletion of T1/ST21 cells (Fig. 7 B; P 5
0.07). Therefore, the proportion of recovered T1/ST21
cells from eosinophilic mice is reduced by IL-12 treatment.
As shown in Fig. 2 and Fig. 7 C, anti-T1/ST2 treatment
prevented weight loss in G/RSV-infected mice. IL-12
treatment of G-primed mice enhanced weight loss during
RSV challenge, as previously described (34). However,
blocking of anti-T1/ST2 had no effect on IL-12–enhanced
weight loss in G/RSV mice (Fig. 7 C). Therefore, al-
though anti-T1/ST2 treatment prevented weight loss in
G/RSV mice, it had no effect when the immune response
to the G protein is altered by IL-12 and skewed towards a
Th1 phenotype or dominated by CD81 T cells.
Discussion
Our results show that anti-T1/ST2 treatment reduces
the severity of Th2-mediated eosinophilic immunopathol-
ogy in the BALB/c mouse model of RSV infection. Treat-
ment decreased weight loss, local recruitment of inflamma-
tory cells (including eosinophils), and lung lavage levels of
IL-5, TNF, and IFN-g in RSV-infected mice presensitized
with the attachment protein G. However, no benefit of
anti-T1/ST2 treatment was found in the noneosinophilic
immunopathology seen in F/RSV mice or in G/RSV mice
previously treated with IL-12.
Previous studies show that T1/ST2 is preferentially ex-
pressed on T cells that predominantly produce IL-4, IL-5,
or IL-10 but not IFN-g or IL-2 (15). Expression is found
in Th2-induced granulomatous lung disease of Schistosoma
mansoni infection (14), and in vitro studies demonstrate up-
regulation of T1/ST2 under Th2-polarizing conditions
(11). Signaling through T1/ST2 after adoptive transfer of
OVA-treated dendritic cells is essential for sensitization to
inhaled OVA and development of Th2-dependent airway
eosinophilia (37). In this study, T1/ST2 expression was
only observed in G protein–sensitized (eosinophilic) mice
and not in those previously sensitized with the fusion pro-
tein or those experiencing a primary RSV infection (both
noneosinophilic). These results, together with the observa-
tion that IL-12 treatment reduces T1/ST2 expression in
G/RSV-infected mice, support the Th2-restricted nature
of this molecule.
The ability of anti-T1/ST2 antibody treatment of
G/RSV-infected mice to abrogate T1/ST2 expression on
BAL cells does not clarify whether T1/ST21 cells are de-
pleted or the receptor merely masked by the antibody. The
effect on Th2-mediated responses was striking, however.
Anti-T1/ST2 treatment was accompanied by a reduction
in IL-5, TNF, and IFN-g but not IL-4 levels in the lung
lavage of G/RSV-infected animals. The reduction in pul-
Figure 5. Anti-T1/ST2 treatment has no effect on the influx of cells
into the lungs of mice primed with the fusion protein. Mice were scari-
fied with Fvac and intranasally challenged with RSV 14 d later. Mice
were treated with rat Ig or anti-T1/ST2 as shown. The number of total
cells, lymphocytes, and CD41 and CD81 T cells was determined as de-
scribed in Fig. 3. The results represent the mean and standard deviation of
groups of five mice. Similar results were obtained in a separate experi-
ment containing four mice per group.
Table I. Depletion of T1/ST2 Reduces Antibody Titers in 
G/RSV-infected Mice 
Mouse group Endpoint antibody titer*
F/RSV control 1/3,218 6 1/1,121
F/RSV 1 anti-T1/ST2 1/3,413 6 1/916
G/RSV control 1/1,638 6 1/458
G/RSV 1 anti-T1/ST2  1/107 6 1/37
Mice were scarified with Gvac or Fvac and intranasally infected with
whole RSV after 14 d. Mice were treated with anti-T1/ST2 or control
Ig as indicated. Serum was removed 7 d after the intranasal RSV
challenge and tested in an RSV-specific ELISA. 
*The endpoint titer represents the final dilution of serum that gave an
optical density reading of 23 the reading obtained with serum from
an uninfected mouse. Results represent the mean and standard devia-
tion of four mice per group and are representative of two independent
experiments.
Figure 6. Anti-T1/ST2 treat-
ment slows the elimination of
RSV from the lungs in eosino-
philic mice. Mice were scarified
with Fvac (diamonds) or Gvac
(squares) and challenged with
RSV 14 d later. At the time
points shown, lungs were re-
moved from rat Ig–treated
(closed symbols) or anti-T1/
ST2–treated (open symbols)
mice. Homogenized lung was
assessed for the presence of RSV
by plaque assay on HEp-2 cells.
The results represent the mean
from four individual mice.
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monary eosinophilia may be explained by reduced IL-5
and is similar to that reported in T1/ST2 knockout mice
infected with S. mansoni eggs (24). The reduction in both
Th1 and Th2 cytokines is intriguing considering that re-
duced IL-4 and IL-5 but increased IFN-g is observed when
OVA-specific Th2 cells are incubated with a T1/ST2 Ig
fusion protein in vitro (11). When OVA-specific cells are
adoptively transferred, however, T1/ST2 depletion reduces
Th2 cytokine levels in the lung lavage but does not signifi-
cantly alter IFN-g. Mediastinal lymph node cells from T1/
ST2 knockout mice produce less IL-4 and IL-5 and in-
creased IFN-g in response to S. mansoni eggs (38). The dis-
crepancies between our results and those of others are
likely to reflect the nature of the antigen (i.e., replicating
versus nonreplicating) and the infected cell type. Our re-
sults also suggest that removal of T1/ST2-expressing cells
does not necessarily enhance Th1 responses. The G protein
only induces CD41 T cells and, in the absence of CD81 T
cells, these assume a Th2 cytokine profile (36). As anti-T1/
ST2 treatment was performed during the RSV challenge
(not during recombinant vaccinia priming), the induction
of a replacement Th1 population would not be anticipated.
The lack of an effect on IL-4 in lavage fluid of anti-T1/
ST2–treated, G/RSV-infected mice may indicate IL-4
production by an alternative cell type. CD41NK1.11 cells
secrete IL-4 but are T1/ST22 (15) and would therefore not
be inhibited in our experimental design.
The reduced weight loss in the G/RSV group treated
with anti-T1/ST2 may be linked to lower TNF levels.
TNF has multiple actions and plays a critical role in inflam-
mation. TNF also plays an important role in recruitment of
cells to normal and inflamed tissues (39, 40) and may induce
early neutrophil and eosinophil recruitment (41). When re-
leased in large quantities, it enters the bloodstream and is as-
sociated with weight loss and cachexia. TNF production is
seen predominantly, but not exclusively, in T1/ST22CD41
T cells (14), and the reduced levels of this cytokine may be
due in part to the decreased total inflammatory cell recruit-
ment seen with T1/ST2 depletion in this study. A reduc-
tion in S. mansoni–induced primary granuloma volume in
T1/ST2 knockout mice (24) is also consistent with the re-
duced inflammatory infiltrate seen in our study. No previ-
ous reports show a decrease in TNF by T1/ST2 inhibition.
T1/ST2 depletion did not inhibit illness in G/RSV-
infected mice treated with IL-12 or those previously sensi-
tized with the F protein. As IL-12 treatment reduces T1/
ST21 cells and such cells are scarce in F protein–sensitized
mice, anti-T1/ST2 treatment does not alter total cell re-
cruitment to the lung and weight loss remains unaltered.
An enhanced T cell–dependent antibody response occurs
in G/RSV-infected mice and promotes rapid viral clear-
ance compared with mice experiencing a primary infection
(b gal/RSV). Considering the reduced T cell recruitment
to the lung, it is not surprising that anti-T1/ST2 treatment
decreases RSV-specific antibody production and delays vi-
ral clearance. To our knowledge, there are no previous re-
ports of delayed clearance of a pathogen due to anti-T1/
ST2 treatment. As illness in this model does not depend on
uncontrolled viral replication but rather on the extent of
cell recruitment, the beneficial effects of T1/ST2 inhibition
are not offset by the delayed viral clearance. A reduction in
antibody has previously been observed in OVA-challenged
mice after T1/ST2 depletion (11) but not in T1/ST2
knockout animals infected with S. mansoni (24).
Studies of T1/ST2-knockout mice have produced con-
flicting results. One group reported that T1/ST2-deficient
animals fail to show decreased Th2 cytokine or Ig produc-
tion in response to Nippostrongylus braziliensis infection or
allergen-induced airway inflammation (25). An indepen-
dently derived T1/ST2 knockout model, however, shows
that basal immunological functions are not affected but that
Th2 cytokine responses are impaired in a fashion similar to
that seen in depletion studies. The findings in the latter
study suggest that this molecule plays an important role in
the early events of Th2 development, as primary but not
Figure 7. Anti-T1/ST2 treatment does not alter illness in IL-12–
treated mice. Mice were scarified with Gvac on day 0 and treated with
PBS (2) or IL-12 (1) from days 22 to 12. RSV was administered intra-
nasally on day 14, and lung lavage was performed after a further 7 d. Total
viable cells (A) were determined by trypan blue exclusion, and the per-
cent eosinophilia (B) was determined by histological analysis of hematox-
ylin and eosin–stained cytocentrifuge preparations. Anti-T1/ST2 treat-
ment decreased the percentage of eosinophils (P 5 0.005), as did IL-12
treatment alone, but IL-12 treatment in conjunction with anti-T1/ST2
did not further decrease this percentage. Weight loss (C) was monitored
throughout RSV challenge and represents the percentage of initial start-
ing weight. Open symbols represent mice treated with anti-T1/ST2 anti-
body; closed symbols represent mice treated with rat Ig. Circles represent
IL-12–treated mice; PBS control mice are represented by squares. The
mean and standard deviation of five individual mice is shown.
791 Walzl et al.
secondary granuloma formation was of decreased magni-
tude (24). In another study, both a T1/ST2-deficient
mouse strain and a transgenic mouse strain expressing high
levels of an extracellular T1/ST2 domain–Fc fusion protein
(acting as T1/ST2 ligand scavenger) cleared N. brasiliensis
infection as efficiently as control mice. Lung lymphocytes,
however, did produce less IL-5, and these mice had a
slightly diminished recruitment of eosinophils into the lung
(26). As T1/ST2 is not only expressed on CD41 T cells but
also on mast cells and fibroblasts (42), the knockout mice
may not only reflect T helper cell phenotype modulation
but also harbor other developmental changes.
Inhibition of specific Th cell phenotypes is a promising
approach to the treatment of various inflammatory condi-
tions. Th2 inhibition may be beneficial in both prevention
and management of allergic inflammation, but to date
treatments have not been able to reliably counter Th2-
driven illness in the clinical setting. T1/ST2 neutralization
may offer a new therapeutic opportunity, but more infor-
mation is needed to define its role. In these studies, we
have been able to demonstrate a beneficial role for anti-
T1/ST2 antibody treatment in selective Th2-directed im-
munopathology in G-primed mice during RSV infection.
Our results offer the prospect that selective anti-T1/ST2
treatment will be beneficial in Th2-driven conditions.
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